Estradiol modulates resting-state connectivity in perimenopausal depression

Area of Science:

• Neuroscience
• Endocrinology
• Psychiatry

Background:

• The perimenopausal transition increases the risk of affective dysregulation and major depressive disorder (MDD).
• Estradiol (E2) replacement therapy is a potential treatment for perimenopausal-onset MDD (PO-MDD), but its neural mechanisms are unclear.
• Previous research suggests E2 influences mood by modulating cortico-subcortical brain connectivity.

Purpose of the Study:

• To investigate the effects of transdermal E2 on resting-state functional connectivity (rsFC) in perimenopausal women.
• To compare rsFC patterns in women with and without PO-MDD before and after E2 treatment.
• To explore the relationship between E2-induced rsFC changes and mood symptom trajectories.

Main Methods:

• Pharmaco-fMRI study involving 16 women with PO-MDD and 18 controls.
• rsFC analysis was conducted before and after three weeks of transdermal E2 administration.
• Seed regions were selected within reward and emotion processing networks (amygdala, caudate nucleus, putamen).

Main Results:

• Pre-treatment: PO-MDD group showed altered amygdala connectivity compared to controls.
• Post-treatment: E2 administration induced significant changes in rsFC in the PO-MDD group, including altered connectivity in the caudate nucleus, putamen, and amygdala.
• Connectivity changes predicted symptom improvements in anhedonia, depressive mood, somatic, and vasomotor domains.

Conclusions:

• Distinct rsFC patterns characterize PO-MDD, and these patterns shift with E2 treatment.
• E2 treatment may alleviate PO-MDD symptoms by modulating cortico-subcortical functional connectivity.
• These findings provide insights into the neural mechanisms underlying E2's mood-modulating effects in perimenopausal depression.